Curis Lifesciences Limited is a pharmaceutical manufacturer engaged in the development, production, and distribution of a diverse range of medicines. Established in 2010, the company operates in both domestic and international markets, offering products such as tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments. It has a strong client base through loan licence and contract manufacturing, along with its own brand marketing operations in select overseas markets. The company’s manufacturing facility in Gujarat follows strict quality control measures and regulatory standards, which help maintain the efficacy and safety of its products. With steady financial growth and a presence in multiple therapeutic segments, Curis Lifesciences continues to strengthen its position in the pharmaceutical manufacturing space.
Investors can apply for the Curis Lifesciences IPO through their bank’s net banking facility using the ASBA (Application Supported by Blocked Amount) process or via stockbroking platforms such as Zerodha, Upstox, Angel One, or Groww. To apply, log in to your preferred platform, choose the IPO section, select “Curis Lifesciences Limited,” enter the number of lots, confirm the bid price, and submit the application. Upon successful submission, the bid amount will be blocked in your linked bank account until the IPO allotment process is completed
For more details, visit the Curis Lifesciences IPO page.
Curis Lifesciences IPO Details and Objectives
Details
| Information
|
IPO Date
| November 7, 2025 to November 11, 2025
|
Issue Size
| 21,50,000 shares
(aggregating up to ₹27.52 Cr)
|
Price Band
| ₹120 to ₹128 per share
|
Lot Size
| 1000 shares
|
Listing At
| SME NSE
|
Market Maker
| RS Wealth Management Private Limited
|
Purpose of the IPO
Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities
Capital Expenditure towards Construction of a Storage Facility
Pre-payment/Repayment of outstanding Secured Loans
Product Registrations in other countries
Funding our Working Capital Requirements
General Corporate Purposes
Timeline of Curis Lifesciences IPO
Event
| Date
|
|---|
IPO Open Date
| Fri, Nov 7, 2025
|
IPO Close Date
| Tue, Nov 11, 2025
|
Tentative Allotment
| Wed, Nov 12, 2025
|
Initiation of Refunds
| Thu, Nov 13, 2025
|
Credit of Shares to Demat
| Thu, Nov 13, 2025
|
Tentative Listing Date
| Fri, Nov 14, 2025
|
Cut-off time for UPI mandate confirmation
| 5 PM on Tue, Nov 11, 2025
|
Pricing & Lot Size of Curis Lifesciences IPO
Price Band for the IPO
Minimum Lot Size and Application Details
Application
| Lots
| Shares
| Amount
|
Individual investors (Retail) (Min)
| 2
| 2,000
| ₹2,56,000
|
Individual investors (Retail) (Max)
| 2
| 2,000
| ₹2,56,000
|
S-HNI (Min)
| 3
| 3,000
| ₹3,84,000
|
S-HNI (Max)
| 7
| 7,000
| ₹8,96,000
|
B-HNI (Min)
| 8
| 8,000
| ₹10,24,000
|
Curis Lifesciences IPO Application Process
The Curis Lifesciences IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Step 1: Login to Your Trading Platform
Access your trading account using the broker's app or website.
Step 2: Navigate to the IPO Section
Go to the IPO section to view active IPO listings.
Step 3: Select the Open IPO and Click Apply
Locate Curis Lifesciences IPO in the list of available IPOs and click the ‘Apply’ button.
Step 4: Enter the Quantity of Shares You Wish to Apply For
Specify the number of shares (minimum lot size: 1000 shares) within the price band of ₹120 to ₹128 per share.
Step 5: Provide Your UPI ID
Enter your UPI ID for payment authorization and ensure sufficient funds in your bank account.
Step 6: Confirm the Application
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Step 7: Complete the Process and Wait for Allotment
Submit the application and monitor the allotment status to check if shares have been allocated to you.
Financial Health and Performance
Key Financial Metrics
Total Assets: Grew from ₹29.75 crore in FY23 to ₹56.29 crore as of July 2025.
Total income: Reached ₹19.51 crore in FY25.
Profit After Tax (PAT): Stood at ₹2.87 crore for July 2025.
Net Worth: Recorded at ₹19.10 crore in FY25.
Reserves and Surplus: Recorded at ₹13.16 crore (July 2025), growing steadily over the years.
EBITDA: Stood at ₹4.24 crore in July 2025.
Recent Performance and Growth Prospects
The company has shown steady expansion in its asset base, reflecting consistent business growth and efficient resource management.
Its total income has witnessed an upward trend, indicating sustained demand for its products and stable operational performance.
Profit levels have remained healthy, suggesting improved cost management and operational efficiency.
The company’s net worth has strengthened, supported by a rise in retained earnings and reserves over time.
Reserves and surplus have grown steadily, showcasing financial stability and prudent management practices.
The company’s earnings before interest, tax, depreciation, and amortisation (EBITDA) indicate a sound operating performance and a strong foundation for future scalability.
Overall, Curis Lifesciences Limited reflects a pattern of consistent growth and improving financial strength, positioning it for further expansion in the coming years.
Investment Risks and Opportunities
Potential Risks of Investing in the IPO
The company’s operations depend significantly on third-party clients for contract and loan licence manufacturing, which may lead to fluctuations in demand and revenue.
Any delays in regulatory approvals, changes in compliance norms, or quality-related issues could affect manufacturing timelines and overall business performance.
Opportunities and Growth Potential
With the planned utilisation of IPO proceeds for facility upgrades, new storage construction, and product registrations in other countries, the company aims to enhance its production capabilities and expand its market presence.
Increasing global and domestic demand for pharmaceutical formulations, coupled with the company’s focus on diversification and compliance-driven growth, may support long-term business sustainability.
Key Performance Indicator (KPI)
KPI
| Values
|
ROE
| 55.25%
|
ROCE
| 27.83%
|
Debt/Equity
| 0.96
|
RoNW
| 37.62%
|
PAT Margin
| 12.43%
|
EBITDA Margin
| 19.41%
|
Price to Book Value
| 12.64
|
Market Capitalization
| 103.48
|
Curis Lifesciences IPO Registrar & Lead Managers
Registrar
| Lead Manager(s)
|
|---|
MUFG Intime India Pvt.Ltd.
| Finaax Capital Advisors Private Limited
|
Company Address of Curis Lifesciences Ltd
Curis Lifesciences Ltd. PF-23, GIDC Sanand - II, Industrial Estate, Sanand Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/
Conclusion
Curis Lifesciences Limited operates in the pharmaceutical manufacturing space, offering a range of formulations across domestic and international markets. The company’s operations are diversified through loan licence manufacturing, contract production, and its own brand marketing, supported by a compliant manufacturing facility in Gujarat. Its financial records reflect consistent business activity and controlled operational practices.
The IPO aims to generate funds for facility improvements, storage infrastructure, loan repayment, and product registration in new markets. With defined objectives and a structured financial approach, the offering represents a part of the company’s plan to strengthen its operational base and maintain stability within the sector.
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Curis Lifesciences IPO allotment status.